Scientists test how Anti-Viral drug reaches unborn babies
NCT ID NCT04732260
Summary
This study measured how much of an experimental anti-CMV drug reaches the fetus when taken by pregnant women. It involved 7 women in their second trimester who were already scheduled for pregnancy termination due to fetal abnormalities. Researchers gave participants the drug for 3 days before the procedure, then measured drug levels in fetal blood, amniotic fluid, and placenta to understand how well it crosses to the baby.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANT WOMEN UNDERGOING TOP are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Necker - Enfants malades
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.